Cancer Immunotherapy Month

Cancer Immunotherapy Month

June was Cancer Immunotherapy Month

Why We Supported the Cancer Research

Adaptimmune supported Cancer Immunotherapy Month, organized by the Cancer Research Institute. To learn more about what we did in 2018 and 2019, click here.

Why We Supported This Campaign

Every day, we work to transform T-cell therapy, which we believe may become one of the pillars of cancer immunotherapy. We focus on the needs of our patients, knowing that what we do can contribute to supporting them in achieving their goals.

Recently, we invited a patient and their physician, who participated in one of our clinical trials, to come and talk to us about living with and treating cancer. We did this to help us understand the needs of our patients so that we can improve their experience with our therapies. Being part of Cancer Immunotherapy Month is another way for us to reinforce the message that everything we do is with the aim to deliver for cancer patients.

As one of the leaders in T-cell therapy, with clinical trials ongoing for multiple proprietary SPEAR T-cells in solid cancer tumor indications, we believe that fostering a broad understanding of TCR technology and the role of T-cells in the immune system is important. We see the Cancer Research Institute's reach and ability to educate and distill these concepts to the medical and the patient community, as key to improve understanding and acceptance of T-cell therapies.

Cancer Research

About the Cancer Research Institute

The Cancer Research Institute (CRI), established 65 years ago in 1953, is the world's leading nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 26 members of the National Academy of Sciences, CRI has invested $357 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to